Vaxart is a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology proprietary oral vaccine platform. Co.'s oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Co.'s investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. In addition, Co. is in early development of its first therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus.